Tirzepatide is the active ingredient in Mounjaro and Zepbound, and it has reset expectations for what a single metabolic drug can do. The reason sits in its mechanism of action: unlike earlier medications that target one incretin hormone, tirzepatide activates two receptors at once. This "dual agonist" or "twincretin" design is what sets it apart from drugs like semaglutide. Here is how it actually works, step by step.
For context on how it compares to other metabolic peptides, see our tesamorelin guide and the popular peptides overview.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide based on the structure of GIP, one of the body's natural incretin hormones. A fatty-acid chain attached to the peptide lets it bind to albumin in the blood, which extends its half-life to around five days and allows once-weekly subcutaneous dosing.
Crucially, it is engineered to activate two receptors: the GIP receptor and the GLP-1 receptor. That combination is the heart of its mechanism.
The Two Incretin Hormones It Mimics
Incretins are gut hormones released after you eat. They tell the pancreas to release insulin and help coordinate the body's response to food.
-
GLP-1 (glucagon-like peptide-1): boosts glucose-dependent insulin release, suppresses glucagon, slows stomach emptying, and acts on the brain to reduce appetite.
-
GIP (glucose-dependent insulinotropic polypeptide): also stimulates insulin release, and additionally affects fat tissue metabolism and energy regulation, with emerging evidence it acts in the brain on appetite and nausea.
Older drugs (semaglutide, liraglutide) target only GLP-1. Tirzepatide engages both pathways.
Tirzepatide's Mechanism of Action, Step by Step
1. Glucose-dependent insulin secretion
By activating both the GLP-1 and GIP receptors on pancreatic beta cells, tirzepatide amplifies insulin release — but only when blood glucose is elevated. This "glucose-dependent" action is why it lowers high blood sugar without the hypoglycemia risk of some older diabetes drugs.
2. Glucagon suppression
Through the GLP-1 pathway, it reduces glucagon — the hormone that tells the liver to release stored glucose. Less glucagon means less sugar dumped into the bloodstream, especially after meals.
3. Slower gastric emptying
It slows how quickly the stomach empties, which blunts post-meal glucose spikes and prolongs the feeling of fullness. This also explains the gastrointestinal side effects, which are most common early on.
4. Appetite regulation in the brain
Both receptors are present in brain regions that control hunger and satiety. Activating them reduces appetite and food intake — the main driver of the weight loss seen in trials. There is evidence the GIP component may also reduce the nausea that GLP-1 activation can cause, improving tolerability.
5. Effects on fat tissue and insulin sensitivity
The GIP receptor is expressed in adipose tissue, where tirzepatide appears to improve how fat cells handle lipids and respond to insulin. This is one proposed reason the dual approach may improve metabolic markers beyond what GLP-1 activation alone achieves.
Why Dual Action May Outperform GLP-1 Alone
The theory behind tirzepatide is that GIP and GLP-1 are complementary: GLP-1 drives insulin, satiety and slowed digestion, while GIP adds insulin support, favorable effects on fat metabolism, and possibly better tolerability. Head-to-head, the SURPASS-2 trial compared tirzepatide with semaglutide in type 2 diabetes and found greater reductions in A1c and body weight across tirzepatide doses. In obesity, the SURMOUNT-1 trial reported average body-weight reductions of roughly 15% to 21% at the higher doses over 72 weeks.
| Feature | GLP-1 agonists (e.g. semaglutide) | Tirzepatide |
|---|---|---|
| Receptors targeted | GLP-1 only | GLP-1 + GIP |
| Insulin effect | Glucose-dependent | Glucose-dependent |
| Appetite suppression | Yes | Yes |
| Adipose/insulin-sensitivity effect | Limited | Added via GIP |
| Dosing | Weekly | Weekly |
Approved Uses
Tirzepatide is FDA approved under two brand names:
-
Mounjaro — for type 2 diabetes (approved 2022), as an addition to diet and exercise.
-
Zepbound — for chronic weight management in adults with obesity or overweight with a weight-related condition (approved 2023), and subsequently for moderate-to-severe obstructive sleep apnea in adults with obesity.
It is prescription-only, given as a once-weekly subcutaneous injection, with the dose titrated upward gradually by a prescriber to limit side effects.
Safety at a Glance
The most common side effects are gastrointestinal — nausea, diarrhea, vomiting and constipation — usually mildest when the dose is increased slowly. Labeling carries a boxed warning about thyroid C-cell tumors based on rodent studies, and it is not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis, gallbladder issues and low blood sugar (mainly when combined with other diabetes drugs) are other considerations. Because it is a prescription drug, use should always be supervised by a healthcare provider.
Legal Status
Unlike most research peptides, tirzepatide is an approved prescription medicine, not a research chemical. It is legally available only through a prescription and licensed pharmacy. For how this differs from the regulatory status of research peptides, see our guide on whether peptides are legal in the US.
Frequently Asked Questions
How does tirzepatide work?
It is a dual agonist that activates both the GIP and GLP-1 receptors. Together these increase glucose-dependent insulin release, suppress glucagon, slow stomach emptying, and reduce appetite through the brain, which lowers blood sugar and drives weight loss.
What is the difference between tirzepatide and semaglutide?
Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors. In head-to-head trials, tirzepatide produced greater reductions in A1c and body weight.
What does "dual GIP/GLP-1 agonist" mean?
It means a single molecule that switches on two different incretin hormone receptors at once, rather than just one. This is why tirzepatide is sometimes called a "twincretin."
Is tirzepatide FDA approved?
Yes. It is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity.
Disclaimer
This article is for educational and informational purposes only and is not medical advice. Tirzepatide is an FDA-approved prescription medication that should be used only under the supervision of a licensed healthcare provider. The Peptide Library is an educational resource; consult your doctor before starting, stopping or changing any medication.
References
-
Tirzepatide's Mechanism of Action, GoodRx.
-
Mounjaro: Uses, Dosage, Side Effects & Warnings, Drugs.com.
-
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
-
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.